Biogen Idec Plans Multiple Sclerosis Portfolio Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.